Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12
暂无分享,去创建一个
[1] Ayalew Tefferi,et al. Myeloproliferative Neoplasms A Contemporary Review , 2015 .
[2] M. Sáez,et al. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study , 2015, Leukemia & lymphoma.
[3] F. Climent,et al. WHO‐histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes , 2014, British journal of haematology.
[4] Bernd Holleczek,et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. , 2014, The Lancet. Oncology.
[5] Mike Clarke,et al. How common are myeloproliferative neoplasms? A systematic review and meta‐analysis , 2014, American journal of hematology.
[6] J. Cerhan,et al. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort , 2014, International journal of cancer.
[7] U. Iqbal,et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union , 2014, European journal of haematology.
[8] R. Walgren,et al. Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN) , 2014, PloS one.
[9] Hongwei Wang,et al. Epidemiology of myeloproliferative neoplasms in the United States , 2014, Leukemia & lymphoma.
[10] T. Barbui,et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms , 2014, Leukemia.
[11] H. Brenner,et al. Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century , 2013, Journal of Hematology & Oncology.
[12] M. Björkholm,et al. No familial aggregation in chronic myeloid leukemia. , 2013, Blood.
[13] D. Neuberg,et al. Trends in all‐cause mortality among patients with chronic myeloid leukemia , 2013, Cancer.
[14] V. Beral,et al. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study , 2013, British Journal of Cancer.
[15] O. Bjerrum,et al. Inheritance of the chronic myeloproliferative neoplasms. A systematic review , 2013, Clinical genetics.
[16] R. Sankila,et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study , 2013, Haematologica.
[17] S. Devesa,et al. Epidemiology and Hereditary Aspects of Acute Leukemia , 2013 .
[18] T. Barbui,et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). , 2012, Blood.
[19] J. Ha,et al. Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms , 2012, Annals of laboratory medicine.
[20] V. Beral,et al. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study , 2012, British Journal of Cancer.
[21] J. Reilly,et al. Improving survival trends in primary myelofibrosis: an international study. , 2012, Journal of Clinical Oncology.
[22] P. Dickman,et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. Gale,et al. Unique features of primary myelofibrosis in Chinese. , 2012, Blood.
[24] M. Mills,et al. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms , 2012, American journal of hematology.
[25] C. Cogle,et al. Underreporting of Myeloid Malignancies by United States Cancer Registries , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[26] S. Devesa,et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. , 2012, Blood.
[27] Alexandra G. Smith,et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network , 2011, British Journal of Cancer.
[28] T. Barbui,et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P. Johansson,et al. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera , 2011, European journal of haematology.
[30] T. Petrella,et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Côte d’Or (Burgundy, France) , 2011, Haematologica.
[31] A. Polednak. US death rates from myeloproliferative neoplasms, and implications for cancer surveillance. , 2011, Journal of registry management.
[32] F. Berrino,et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.
[33] M. Cazzola,et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.
[34] N. Freedman,et al. Sex Disparities in Cancer Incidence by Period and Age , 2009, Cancer Epidemiology Biomarkers & Prevention.
[35] Xiaomei Ma,et al. Jakking up tumor registry reporting of the myeloproliferative neoplasms , 2009, American journal of hematology.
[36] C. Pascutto,et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients , 2008, Haematologica.
[37] M. Björkholm,et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. , 2008, Blood.
[38] P. Emanuel. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia , 2008, Leukemia.
[39] N. Howlader,et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.
[40] S. Devesa,et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology , 2007, British journal of haematology.
[41] T. Cenci,et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] D. Larson,et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. , 2006, Mayo Clinic proceedings.
[43] H. Møller,et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East-England. , 2006 .
[44] H. Møller,et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. , 2006, Haematologica.
[45] D. Weisenburger,et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.
[46] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[47] C. Kirkpatrick,et al. The Incidence of Myelofibrosis in Essential Thrombocythaemia, Polycythaemia vera and Chronic Idiopathic Myelofibrosis: A Retrospective Evaluation of Sequential Bone Marrow Biopsies , 2005, Acta Haematologica.
[48] M. Cazzola,et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.
[49] M. Gershwin,et al. Inflamm-aging: autoimmunity, and the immune-risk phenotype. , 2004, Autoimmunity reviews.
[50] C. Stiller,et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population‐based study of incidence and survival , 2003, British journal of haematology.
[51] E. Feuer,et al. Impact of reporting delay and reporting error on cancer incidence rates and trends. , 2002, Journal of the National Cancer Institute.
[52] P. Wollan,et al. Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976–1995 , 1999, American journal of hematology.
[53] J. Hasford,et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.
[54] J. Harbott,et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.
[55] J. Harbott,et al. Chronic myelomonocytic leukemia in childhood. A retrospective analysis of 110 cases. , 1997 .
[56] J. Laszlo,et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.
[57] Gruppo Italiano Studio Policitemia. Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years , 1995, Annals of Internal Medicine.
[58] T. Fears,et al. Graphical presentation of trends in rates. , 1995, American journal of epidemiology.
[59] O. Zettervall,et al. Incidence of polycythemia vera in a defined population , 1992, European journal of haematology.
[60] E. Feliú,et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders , 1991, Cancer.
[61] M. Baccarani,et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. , 1984, Blood.
[62] P. Trott,et al. International Classification of Diseases for Oncology , 1977 .
[63] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.